The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

Scientists from a German-Swiss consortium have developed miniature antibody-like proteins, called DARPins, that can stabilize and reactivate multiple mutated forms of the p53 tumor suppressor protein ...

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...

(TP53), widely known as the “guardian of the genome,” is one of the most frequently altered genes in human cancer. While its canonical tumor-suppressive ...

This review illustrates how the nuclear phosphoinositide-p53 signalosome integrates lipid signaling and p53 function to regulate cancer cell motility. The figure contrasts the tumor-suppressive ...

The protein p53 is mutated in many cancer cells, meaning it can no longer fulfill its protective function against tumor development. A team of scientists from Goethe University Frankfurt, along with ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

On April 29, separate teams and agencies announced three developments in cancer science: a new DARPin-based method to restore tumor suppressor p53 function, a U.S. FDA pilot for real-time monitoring ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

A novel peptide therapy shuts down tumor energy production by targeting ATP synthase in mitochondria. The approach decreased ...